EMEA
-
AMT Receives Orphan Drug Designation for DMD Treatment
Amsterdam Molecular Therapeutics (AMT) has announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to the former’s gene therapy product AMT-080 for the treatment of Duchenne Muscular Dystrophy (DMD). Orphan Drug …
EMEA | 22 October 2009
-
First melatonergic antidepressant receives EU CHMP positive opinion
The first melatonergic antidepressant Valdoxan/Thymanax (agomelatine) has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients w…
EMEA | 26 November 2008
